Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Braksurf versus Curosurf for neonatal respiratory distress syndrome
IRCT20170427033661N2Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Length of hospital stay, Need for mechanical ventilation and 3 more. Started Dec 2020; status: completed.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20170427033661N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170427033661N2.